Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

[1]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[3]  Shamim A. Mollah,et al.  Flt3L-dependence helps define an uncharacterized subset of murine cutaneous dendritic cells , 2013, The Journal of investigative dermatology.

[4]  J. Sosman,et al.  The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma , 2013, Nature Reviews Clinical Oncology.

[5]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[6]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[7]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[8]  P. Hwu,et al.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.

[9]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[10]  T. Sakurai,et al.  Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells , 2012, The Journal of Immunology.

[11]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[12]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[13]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[14]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[15]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[16]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[17]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[18]  L. Yao,et al.  N-myc Downstream-regulated Gene 2, a Novel Estrogen-targeted Gene, Is Involved in the Regulation of Na+/K+-ATPase* , 2011, The Journal of Biological Chemistry.

[19]  P. Coulie,et al.  Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? , 2011, Cancer Immunology, Immunotherapy.

[20]  F. Gounari,et al.  β-Catenin Inhibits T Cell Activation by Selective Interference with Linker for Activation of T Cells–Phospholipase C-γ1 Phosphorylation , 2011, The Journal of Immunology.

[21]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[22]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[23]  S. Tippmer,et al.  Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075 , 2010, The Journal of Immunology.

[24]  P. Rod Dunbar,et al.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens , 2010, The Journal of experimental medicine.

[25]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[26]  A. Brooks,et al.  Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells , 2009, Nature Immunology.

[27]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[28]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[29]  T. Jacks,et al.  Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. , 2008, Cancer research.

[30]  E. Unanue,et al.  Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.

[31]  Christian von Mering,et al.  STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..

[32]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[33]  Tsonwin Hai,et al.  Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. , 2007, Molecular immunology.

[34]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[35]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[36]  L. Chin,et al.  Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice , 2006, Genesis.

[37]  Toyoaki Tenzen,et al.  Hedgehog signaling in the neural crest cells regulates the patterning and growth of facial primordia. , 2004, Genes & development.

[38]  A. Sher,et al.  CCR5 provides a signal for microbial induced production of IL-12 by CD8α+ dendritic cells , 2000, Nature Immunology.

[39]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[40]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[41]  D. Kranz,et al.  Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. , 1997, Journal of immunology.

[42]  W. Sellers,et al.  Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia , 2002, Oncogene.

[43]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .